Video

Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLC

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Terence T. Sio, MD, MS, radiation oncologist and assistant professor of radiation oncology at Mayo Clinic, discusses the standard-of-care dose of radiation therapy in locally advanced, non—small cell lung cancer (NSCLC).

In the modern era, the standard-of-care for patients with locally advanced NSCLC who require concurrent chemotherapy and radiation therapy is 60 gray (Gy), says Sio. This dosage is delivered Monday through Friday, at 2 Gy/day per fraction, for the duration of 6 weeks.

The NRG Oncology RTOG 0617 trial set out to determine whether a higher dose of radiation, 74 Gy, with concurrent chemotherapy would be more beneficial than the standard dose of 60 Gy, in patients with unresectable stage III NSCLC, says Sio. Investigators noted more adverse events in those who received the higher dose, with no improvement in overall survival. As such, 60 Gy continues to be the standard-of-care radiation dose in this patient population, concludes Sio.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

May 15th 2025 - May 16th 2026

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer
Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

May 15th 2025 - May 16th 2026

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

May 14th 2025 - Jun 19th 2025

online-activity